4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

Company Overview

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas. Notable programs target inherited retinal disorders—such as X-linked retinitis pigmentosa and achromatopsia—as well as investigational candidates for neuromuscular and metabolic diseases. By tailoring capsid design to specific tissues, the company seeks to optimize safety and efficacy in patient populations with high unmet medical need.

To support its research and development efforts, 4D Molecular Therapeutics engages in collaborations with academic institutions and industry partners in the United States and Europe. The company completed its initial public offering in October 2017, trading on the NASDAQ under the symbol FDMT, and has used the proceeds to advance its clinical and preclinical programs.

The company is led by President and Chief Executive Officer John J. Falcon, whose leadership team comprises experienced professionals in gene therapy development, regulatory affairs and commercial strategy. Under Falcon’s guidance, 4D Molecular Therapeutics continues to advance its innovative platform with the goal of delivering transformative treatments to patients suffering from rare genetic disorders.

Key Stats

• Today's Range: $9.48 to $9.86
• 50-Day Range: $8.33 to $10.49
• 52-Week Range: $3.00 to $12.34
• Volume: 541,898 shs
• Average Volume: 702,568 shs
• Market Capitalization: $507.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.25
• Consensus Rating: Moderate Buy

4D Molecular Therapeutics Stock Analysis - MarketRank™

4D Molecular Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 667th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

4D Molecular Therapeutics has a consensus price target of $31.25, representing about 221.8% upside from its current price of $9.71.

Amount of Analyst Coverage

4D Molecular Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($3.71) to ($3.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 4D Molecular Therapeutics is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 4D Molecular Therapeutics is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

4D Molecular Therapeutics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.96% of the float of 4D Molecular Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

4D Molecular Therapeutics has a short interest ratio ("days to cover") of 16.29, which indicates bearish sentiment.

Change versus previous month

Short interest in 4D Molecular Therapeutics has recently increased by 6.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

4D Molecular Therapeutics does not currently pay a dividend.

Dividend Growth

4D Molecular Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for 4D Molecular Therapeutics this week, compared to 3 articles on an average week.

Search Interest

12 people have searched for FDMT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 4D Molecular Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,358.00 in company stock.

Percentage Held by Insiders

9.60% of the stock of 4D Molecular Therapeutics is held by insiders.

Percentage Held by Institutions

99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FDMT Stock Analysis - Frequently Asked Questions

How have FDMT shares performed this year?

4D Molecular Therapeutics' stock was trading at $7.50 at the beginning of 2026. Since then, FDMT stock has increased by 29.5% and is now trading at $9.71.

How were 4D Molecular Therapeutics' earnings last quarter?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) released its quarterly earnings data on Wednesday, March, 18th. The company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.96. The business earned $85.09 million during the quarter, compared to analysts' expectations of $30.86 million. 4D Molecular Therapeutics had a negative trailing twelve-month return on equity of 31.75% and a negative net margin of 164.43%.

When did 4D Molecular Therapeutics IPO?

4D Molecular Therapeutics (FDMT) raised $189 million in an IPO on Friday, December 11th 2020. The company issued 8,400,000 shares at a price of $22.00-$23.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

Who are 4D Molecular Therapeutics' major shareholders?

Top institutional investors of 4D Molecular Therapeutics include Bank of New York Mellon Corp (0.26%), Assenagon Asset Management S.A. (0.16%), Simplify Asset Management Inc. (0.14%) and Y Intercept Hong Kong Ltd (0.05%). Insiders that own company stock include Global Investors Lp Viking, David Kirn, Ashoo Gupta, Scott Bizily and Robert Young Kim.
View institutional ownership trends.

How do I buy shares of 4D Molecular Therapeutics?

Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 4D Molecular Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 4D Molecular Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

• Last Earnings: 3/18/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FDMT
• CIK: 1650648
• Web: www.4dmoleculartherapeutics.com
• Phone: 510-505-2680
• Fax: N/A
• Employees: 120
• Year Founded: 2013

Price Target and Rating

• Average Price Target for 4D Molecular Therapeutics: $31.25
• High Price Target: $44.00
• Low Price Target: $17.00
• Potential Upside/Downside: +221.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$140.11 million
• Net Margins: -164.43%
• Pretax Margin: -164.43%
• Return on Equity: -31.75%
• Return on Assets: -28.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.39
• Quick Ratio: 9.39

Sales & Book Value

• Annual Sales: $85.21 million
• Price / Sales: 5.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.85 per share
• Price / Book: 1.10

Miscellaneous

• Outstanding Shares: 52,280,000
• Free Float: 47,257,000
• Market Cap: $507.64 million
• Optionable: Optionable
• Beta: 2.77